Healthcare Industry News: Transdermal System
News Release - April 10, 2007
Brian M. Gallagher Joins Transport Pharmaceuticals' Board of DirectorsFRAMINGHAM, Mass., April 10 (HSMN NewsFeed) -- Transport Pharmaceuticals, Inc., a leader in combination drug/medical devices for the topical treatment of dermatological conditions, today announced the appointment of Brian M. Gallagher, Ph.D., as Director. Dr. Gallagher is currently President and Chief Executive Officer of Magen Biosciences, a dermatology-focused specialty pharmaceutical company. He has more than 25 years of experience in the specialty pharmaceuticals, healthcare and diagnostics industries.
Dennis I. Goldberg, Ph.D., President and Chief Executive Officer of Transport commented on the appointment, "Brian has a long record of success in the specialty pharmaceutical and pharmaceuticals industries. His extensive industry experience will be of great benefit to Transport as we progress our lead product through late-stage clinical trials and proceed with partnering discussions."
"Transport is a leader in the new field of combination drug-device products. The company's pioneering work with electrokinetic transdermal delivery places it at the forefront of this important new field," said Dr. Gallagher. "Transport's lead product, the SoloVir(TM) system, may change the way the world treats herpes labialis. I look forward to working closely with Dennis and the rest of the Board in building a leading dermatology-focused specialty pharmaceutical company."
Prior to joining Magen, Dr. Gallagher was most recently an independent consultant advising specialty pharmaceutical companies and venture capitalist funds. Previously, he served as President, CEO and Chairman of CollaGenex Pharmaceuticals, a specialty pharmaceutical company working in dermatology. Dr Gallagher has also held a number of executive positions at Bristol-Myers Squibb, including President of Squibb Diagnostics. He received his B.S. from St. Louis University and his Ph.D. from St. John's University.
About Transport Pharmaceuticals, Inc.
Transport is bringing together cutting-edge medical electronics with drug formulation and material sciences to develop drug/device combination products that enhance movement of drugs across the stratum corneum (the skin's outer layer) by means of electric current. Transport's lead product, the SoloVir(TM) electrokinetic Transdermal System, utilizes the company's proprietary five-percent acyclovir gel-formulation to treat herpes labialis, or cold sores. Pharmacokinetic data from a recently completed Phase I study indicate that a single ten minute application of SoloVir(TM) delivered more than 100 times the published peak tissue levels (2 ug/ml) of acyclovir achieved with a 1 gram dose of Valtrex®, a leading oral-antiviral drug marketed for the treatment of herpes labialis. In addition, the peak tissue levels are achieved at the time of administration with SoloVir(TM), while orally administered Valtrex® requires more than two hours to reach peak acyclovir levels in the skin.
Transport is a Massachusetts-based, privately-held specialty pharmaceutical company. Current venture investors include Quaker BioVentures, The Carlyle Group, The Hillman Company and The Halleran Company. For more information, please visit http://www.transportpharma.com .
Source: Transport Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.